GEM-DIMER
LIVE

Serial Number

99545865

Owner

Hinge Bio, Inc.

Attorney

Beth M. Goldman

Filing Date

Dec 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

GEM-DIMER Trademark

Serial Number: 99545865

GEM-DIMER is a trademark filed by Hinge Bio, Inc. on December 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Hinge Bio, Inc. (3 trademarks)

Suite 100L
Burlingame, CA 94010

Entity Type: 03

Trademark Details

Filing Date

December 12, 2025

Registration Date

Not Registered

Published for Opposition

June 9, 2026

Goods & Services

Pharmaceutical preparations comprising of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions; pharmaceutical agents comprising of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions; monospecific, bispecific, or multi-specific antibody based molecules as a component in pharmaceutical preparations for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 3, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 11, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 29, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 29, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 29, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 16, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 16, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 16, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 16, 2026 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 10, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 10, 2026 REAP
APPLICATION FILING RECEIPT MAILED
Dec 12, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 12, 2025 NWOS
NEW APPLICATION ENTERED
Dec 12, 2025 NWAP